The CEO's sustained selling under a 10b5-1 plan, especially the large volume over the past week, may signal a lack of near-term confidence. Traders should monitor for further insider filings and any upcoming catalysts (e.g., pipeline updates) that could explain the selling. The 10b5-1 plan provides some cover, but the magnitude is notable for a $3.1B biotech.
Price Chart
Executive Summary
CEO Matthew Kapusta filed a Form 144 to sell 28,716 ordinary shares (~$1.44M) under a 10b5-1 plan adopted in October 2025. This follows substantial recent insider sales totaling over $9M in the past week, including 152,844 shares on June 17 and additional sales on June 18 and June 24. The filing signals continued insider monetization, which may weigh on sentiment given the CEO's role.
Key Facts
- CEO Matthew Kapusta filed Form 144 to sell 28,716 ordinary shares with an estimated market value of $1,436,305.40.
- The sale is part of a 10b5-1 trading plan adopted in October 2025.
- Recent insider sales by Kapusta include: 152,844 shares ($6,724,136.05) on June 17, 11,585 shares ($563,610.25) and 41,671 shares ($1,932,516.28) on June 18, and 6,696 shares ($334,800.00) on June 24.
- Total recent sales by the CEO exceed $11M, representing a material reduction in his stake.
- Market cap is approximately $3.1B, making the proposed sale ~0.046% of market cap, but cumulative sales are more significant.
Financial Impact
CEO intends to sell ~$1.44M in shares; cumulative recent sales exceed $11M.
Risk Factors
- Insider selling may indicate management's view that the stock is fully valued or that near-term risks are elevated.
- Continued selling could create overhang and pressure the stock price.
- The 10b5-1 plan reduces but does not eliminate the negative signal of large CEO sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001973379-26-000254 |
| Document: 0001973379-26-000254-index.html | 0001973379-26-000254 |
| Document: 0001973379-26-000254.txt | 0001973379-26-000254 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $46.23 $44.47 | ▼ −3.81% | ▼ −2.85% | $23.46 (−49.25%) |
Jul 29, 2026 9w ago | 8-K | $40.07 $44.24 | ▲ +10.41% | ▲ +4.88% | $23.46 (−41.45%) |
Jul 7, 2026 12w ago | Insider Cluster | $41.41 $41.52 | ▼ −0.27% | ▲ +0.29% | $23.46 (+43.35%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▼ −6.39% | ▼ −5.46% | $23.46 (+43.89%) |
Jul 2, 2026 13w ago | Insider Cluster | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jul 2, 2026 13w ago | 144 | $41.81 $44.48 | ▲ +6.39% | ▲ +5.46% | $23.46 (−43.89%) |
Jun 30, 2026 13w ago | 144 | $45.17 $41.41 | ▼ −8.32% | ▼ −8.59% | $23.46 (−48.06%) |
Jun 25, 2026 14w ago | 144 | $47.51 $41.81 | ▲ +12.00% | ▲ +14.16% | $23.46 (+50.62%) |
Jun 24, 2026 14w ago | 424B5 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
Jun 24, 2026 14w ago | 144 | $49.10 $45.17 | ▼ −8.00% | ▼ −9.56% | $23.46 (−52.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access